MEDI 9314

Drug Profile

MEDI 9314

Alternative Names: MEDI-9314

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; MedImmune
  • Class Antibodies; Immunotherapies
  • Mechanism of Action Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Atopic dermatitis

Most Recent Events

  • 16 Feb 2016 Preclinical trials in Undefined indication in USA (Parenteral)
  • 20 Jan 2016 MedImmune plans a phase I trial (In volunteers) for Atopic dermatitis in USA and United Kingdom (NCT02669667)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top